Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Oncogene. 2022 Apr 19;41(21):2958–2972. doi: 10.1038/s41388-022-02311-z

Fig. 1. KDM5B expression in cancer and establishment of cancer cell models.

Fig. 1

A Expression analysis of KDM5B in normal and cancer samples. Oncomine was used to analyze public mRNA expression datasets from human cancers (bladder [79], breast-TCGA, leukemia [80], lung [81], ovarian-TCGA, melanoma-TCGA, pancreas [82], prostate [83], renal [84], uterine-TCGA). Boxplots indicate the 1st and 3rd quartiles (25th and 75th percentile, upper and lower bounds), 2nd quartile (center), and minima–maxima (1.5*interquartile range). B Z-score analysis of KDM5B expression in the NCI-60 panel of cancer cell lines. The top panel shows cancer cell lines with the highest expression of KDM5B, while the bottom panel shows cell lines with lower expression of KDM5B. BR breast, ME melanoma, LC lung cancer, CNS brain cancer, OV ovarian, LE leukemia, RE renal, PR prostate, CO colon. C Kaplan–Meier curve for the overall survival of cancer patients exhibiting high (red) or low (black) expression of KDM5B. D Schematic of experimental design. E qRT-PCR expression ±SEM (standard error of mean) of KDM5B in control (shLuc) and KDM5B depleted (shKDM5B) cancer cells (shLuc, Gray; shKdm5b, Black). F Western blot of KDM5B and H3K4me3 (rabbit monoclonal antibody H3K4me3; 17–614) in control and KDM5B depleted cancer cells. HSC70 (sc-7298) and total H3 (sc-517576) antibodies were used for total loading control and nuclear loading control, respectively.